Anti-MAPE / PRAME

In 1X PBS, pH 7.4, with 0.09% sodium azide. MAPE (Melanoma antigen preferentially expressed in tumors), also called PRAME (Preferentially expressed antigen of melanoma), is a protein that is preferentially expressed in tumors, particularly in melanoma. It plays a vital role in regulating cell proliferation, migration, and invasion, making it a promising target for therapeutic interventions. Studies have shown that the overexpression of MAPE protein is associated with aggressive melanoma subtypes, indicating its potential as a prognostic biomarker in melanoma patients. Protein function: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation (PubMed:21822215, PubMed:26138980). The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding (PubMed:26138980). In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromstin regulation (PubMed:21822215). Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis (PubMed:16179254). [The UniProt Consortium]